Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Esperion Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. Its products include ETC-1002, an oral molecule therapy that is in Phase IIb clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic apoA-I therapy that is in pre-clinical trials for treating patients with acute coronary syndrome. The company is headquartered in Plymouth, Michigan.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-12.29%||ROE||-12.71%||ROI|
|Current Ratio||40.33||Quick Ratio||Long Term Debt/Equity||0.01||Debt Ratio||0.02|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||190.41 M||Cash From Investing Activities||-57.55 M||Cash From Operating Activities||-9.26 M||Gross Profit|
|Net Profit||-11.47 M||Operating Profit||-11.43 M||Total Assets||325.22 M||Total Current Assets||279.83 M|
|Total Current Liabilities||6.94 M||Total Debt||4.88 M||Total Liabilities||10.79 M||Total Revenue|
|High 52 week||59.11||Low 52 week||36.99||Last close||37.71||Last change||-3.36%|
|RSI||22.75||Average true range||1.65||Beta||1.81||Volume||98.17 K|
|Simple moving average 20 days||-8.5%||Simple moving average 50 days||-17.36%||Simple moving average 200 days||-18.33%|
|Performance Week||-2.48%||Performance Month||-19.34%||Performance Quart||-24.84%||Performance Half||-16.7%|
|Performance Year||-18.66%||Performance Year-to-date||-18.02%||Volatility daily||1.86%||Volatility weekly||4.15%|
|Volatility monthly||8.51%||Volatility yearly||29.48%||Relative Volume||258.64%||Average Volume||447.01 K|
|New High||New Low|
2020-06-05 11:31:03 | Why Is Esperion Therapeutics ESPR Down 1.5% Since Last Earnings Report?
2020-06-04 12:00:04 | All You Need to Know About Esperion Therapeutics ESPR Rating Upgrade to Buy
2020-05-15 18:00:10 | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635c4
2020-05-08 14:49:46 | Analysts Are Upgrading Esperion Therapeutics, Inc. NASDAQ:ESPR After Its Latest Results
2020-05-07 11:47:03 | Esperion ESPR Q1 Earnings and Revenues Beat Estimates
2020-05-07 09:01:12 | Esperion Therapeutics Inc ESPR Q1 2020 Earnings Call Transcript
2020-05-07 07:29:47 | Edited Transcript of ESPR earnings conference call or presentation 6-May-20 8:30pm GMT
2020-05-06 18:55:10 | Esperion Therapeutics ESPR Reports Q1 Loss, Tops Revenue Estimates
2020-05-06 16:05:10 | Esperion Reports First Quarter 2020 Financial Results and Provides Company Update
2020-04-30 08:00:10 | Esperion to Report First Quarter 2020 Financial Results May 6, 2020
2020-04-20 07:00:10 | Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ bempedoic acid and NEXLIZET™ bempedoic acid and ezetimibe Tablets in Japan
2020-04-18 10:59:36 | Were Hedge Funds Right About Selling Esperion Therapeutics ESPR?
2020-04-07 10:43:02 | Esperion's Cholesterol Drugs Receive Approval in Europe
2020-03-28 11:30:03 | Esperion Therapeutics ESPR Down 32.5% Since Last Earnings Report: Can It Rebound?
2020-03-28 09:30:10 | Esperion Announces Three Data Presentations of the NEXLETOL™ bempedoic acid Tablet and the NEXLIZET™ bempedoic acid and ezetimibe Tablet at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology ACC.
2020-03-23 07:30:10 | Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ bempedoic acid Tablet and Phase 2 Study Results of the NEXLIZET™ bempedoic acid and ezetimibe Tablet to be Presented at the American College of Cardiology’
2020-03-18 07:30:10 | Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors
2020-02-28 16:15:10 | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635c4
2020-02-28 08:12:01 | Esperion ESPR Q4 Earnings and Revenues Beat Estimates
2020-02-28 07:00:10 | Esperion to Participate in Upcoming Investor Conferences
2020-02-27 10:15:03 | Esperion Therapeutics ESPR Reports Q4 Loss, Tops Revenue Estimates
2020-02-21 16:27:15 | Biotech Stock Crumbles Despite Esperion Nabbing A Key Drug Approval
2020-02-16 15:03:32 | The Week Ahead In Biotech: Agile, Baudax Bio, Merck and Esperion Await FDA Decisions
2020-02-03 13:30:16 | Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates
2020-01-31 07:02:10 | Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
2020-01-27 12:20:13 | One Thing To Remember About The Esperion Therapeutics, Inc. NASDAQ:ESPR Share Price
2020-01-07 07:30:10 | Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference
2020-01-03 16:15:10 | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635c4
2019-12-12 11:59:58 | Did Hedge Funds Drop The Ball On Esperion Therapeutics ESPR ?
2019-12-06 11:31:04 | Esperion Therapeutics ESPR Up 25.1% Since Last Earnings Report: Can It Continue?
2019-11-28 07:09:12 | Esperion's Promising Drugs Under Review, Funds a Concern
2019-11-22 18:30:10 | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635c4
2019-11-19 09:13:02 | Esperion Therapeutics ESPR Catches Eye: Stock Jumps 10%
2019-11-17 15:05:00 | Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions
2019-11-10 07:56:48 | President Timothy Mayleben Just Bought Shares In Esperion Therapeutics, Inc. NASDAQ:ESPR